Author(s):
V. Sowmya, G. Bhavana, M. Venkataramana, A. Ganesh, Y. Soudarya
Email(s):
vengaladasusowmya78@gmail.com
DOI:
10.52711/2231-5675.2026.00025 
Address:
V. Sowmya*, G. Bhavana, M. Venkataramana, A. Ganesh, Y. Soudarya
Department of Analysis, Surabhi Dayakar Rao College of Pharmacy, Rimmanaguda, Gawel, Telangana, India.
*Corresponding Author
Published In:
Volume - 16,
Issue - 3,
Year - 2026
ABSTRACT:
Telmisartan and Chlorthalidone in bulk and combined dosage form were analysed and validated using RP-HPLC. A new technique was developed for the simultaneous estimation of this to medications using this method. Telmisartan and chlorthalidone were successfully separated using the following chromatographic conditions. Phenomenex luna c18 4.5mm×250mm 5µm particles size, flow rate 1.0ml/min mobile phase ratio 40:60v/v, acetonitrile TEA buffer pH 4.2, pH was adjusted with orthophosphoric acid detection wavelength 258nm, waters Alliance 2685 separation module, software power 2986 PDA detector. There results showed that the retention times were respectively, 2 and 246 mints. It was discovered that the purity percentage of chlorthalidone and telmisartan were 99.76 and 101.26 percent respectively. The tailing factor and theoretical plates, two system suitability parameters for telmisartan and chlorthalidone were determined to be 5377.
Cite this article:
V. Sowmya, G. Bhavana, M. Venkataramana, A. Ganesh, Y. Soudarya. Development and Validation of RP- HPLC Method for Simultaneous Estimation of Telmisartan and Chlorthalidone in Pharmaceutical Dosage Form. Asian Journal of Pharmaceutical Analysis. 2026; 16(3):167-0. doi: 10.52711/2231-5675.2026.00025
Cite(Electronic):
V. Sowmya, G. Bhavana, M. Venkataramana, A. Ganesh, Y. Soudarya. Development and Validation of RP- HPLC Method for Simultaneous Estimation of Telmisartan and Chlorthalidone in Pharmaceutical Dosage Form. Asian Journal of Pharmaceutical Analysis. 2026; 16(3):167-0. doi: 10.52711/2231-5675.2026.00025 Available on: https://ajpaonline.com/AbstractView.aspx?PID=2026-16-3-1
REFERENCES:
1. World Health Organization. WHO global tuberculosis Report. Geneva: WHO; 2016.
2. Hall RG, Leff RD, Gumbo T. Treatment of active Pulmonary tuberculosis in adults: current standards and Recent advances. Pharma Other. 2009; 29: 1468–1481.
3. O’Neil MJ, editor. The Merck index an encyclopedia of chemicals, drugs, and biologicals. 13th ed. Whitehouse Station (NJ): Merck and Co., Inc.; 2001. p. 1474.
4. Maggi N, Pasqualucci CR, Ballota R, et al. Rifampicin: A new orally active rifamycin. Chemotherapy. 1966; 11: 285–292.
5. Rees RJW, Pearson JMH, Waters MFR. Experimental and Clinical studies on rifampicin in treatment of leprosy. Br Med J. 1970; 1: 89–92.
6. Binda G, Domenichini E, Gottardi A. Rifampicin, a general Review. Arzneim Forsch. 1971; 21: 1907–1977.
7. Pähkla R, Lambert J, Ansko P, et al. Comparative bioavail-Ability of three different preparations of rifampicin. J Clin Pharm Ther. 1999; 24: 219–225.
8. Tsankov N, Angelova I. Rifampin in dermatology. Clin Dermatol. 2003; 21: 50–55.
9. Berning, S.E. The role of fluoroquinolones in tuberculosis today. Drugs 2001; 61: 9–18.
10. Jacobs, M.R. Activity of quinolones against mycobacteria. Drugs 1999; 58: 19– 22. [CrossRef].